Madrigal Pharmaceuticals Inc (MDGL)
220.06
+2.89
(+1.33%)
USD |
NASDAQ |
May 17, 16:00
220.06
0.00 (0.00%)
After-Hours: 20:00
Madrigal Pharmaceuticals SG&A Expense (Annual): 108.15M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 108.15M |
| December 31, 2022 | 48.13M |
| December 31, 2021 | 37.32M |
| December 31, 2020 | 21.86M |
| December 31, 2019 | 22.65M |
| December 31, 2018 | 15.29M |
| December 31, 2017 | 7.672M |
| December 31, 2016 | 9.29M |
| December 31, 2015 | 0.8058M |
| December 31, 2014 | 15.75M |
| December 31, 2013 | 15.70M |
| December 31, 2012 | 11.68M |
| Date | Value |
|---|---|
| December 31, 2011 | 11.55M |
| December 31, 2010 | 11.45M |
| December 31, 2009 | 12.65M |
| December 31, 2008 | 14.74M |
| December 31, 2007 | 14.93M |
| December 31, 2006 | 8.648M |
| December 31, 2005 | 11.28M |
| December 31, 2004 | 7.383M |
| December 31, 2003 | 5.261M |
| December 31, 2002 | |
| December 31, 2001 | 0.124M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
21.86M
Minimum
2020
108.15M
Maximum
2023
47.62M
Average
37.32M
Median
2021
SG&A Expense (Annual) Benchmarks
| Viking Therapeutics Inc | 37.02M |
| Eli Lilly and Co | 6.941B |
| Akero Therapeutics Inc | 31.07M |
| 89bio Inc | 28.97M |
| Geron Corp | 69.14M |